Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Ipsen

Status: Completed

Conditions: Renal Cell Carcinoma

Treatments: Drug: Cabozantinib; Drug: Axitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04637204

CLIN-60000-450

Details and patient eligibility

About

The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).

Enrollment: 1,540 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with initial renal cancer diagnosis
• Patients diagnosed at Stage III or Stage IV (as defined in CAS): as evidence for advanced/metastatic RCC
• For patients with Stage I/II or patients with missing information on Staging
• Patients who received SACT1 treatment following initial renal cancer diagnosis through end of enrolment (31 July 2019)
• Patients who received cabozantinib or axitinib treatment

Exclusion criteria

• Diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of aRCC
• Less than 18 years of age at the time of initial aRCC diagnosis
• SACT treatment more than 30 days prior to initial aRCC diagnosis

Trial design

1,540 participants in 4 patient groups

Subgroup 1

Description:

Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.

Treatment:

Drug: Cabozantinib

Subgroup 2

Description:

Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.

Treatment:

Drug: Axitinib

Subgroup 3

Description:

Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)

Treatment:

Drug: Cabozantinib

Subgroup 4

Description:

Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)

Treatment:

Drug: Axitinib